NanoTemper Technologies offers the Prometheus NT.48, with nanoDSF technology. nanoDSF is the method of choice for easy, rapid and accurate analysis of protein folding and stability. Applications include protein engineering, membrane protein research, formulation development and quality control.
Watch our short movie to learn how to easily run and analyze experiments on the Prometheus NT.48.
This guide provides an overview of the key analytical parameters obtained with Prometheus Panta, their definitions and practical relevance for protein characterization and drug development.
When working with membrane proteins, whether you’re troubleshooting aggregation, testing new solubilization strategies, or deciding when to switch detergents read this guide for practical solutions.
Learn about Prometheus Panta C: A next-generation stability characterization platform that's helping biomanufacturers bring automation into the analytical core of their development and process control
Dr. Marius Müller of Johnson & Johnson Innovative Medicine shares insights from questions about the use of nanoDSF™ technology for ID-testing and at several late stages of biotherapeutics development.
NanoTemper Technologies announces the launch of Prometheus Panta C, a solution designed to meet the evolving needs of biopharmaceutical development—from preclinical phase to commercial manufacturing.
Expert Marius Müller, PhD, Team Lead at Johnson & Johnson Innovative Medicine, shares insights into three significant trends that have potential to reshape the biopharma and biomanufacturing industry
Learn how to enhance your lab's efficiency with Prometheus Panta, from using capillary chips for high-throughput sample loading to solutions for seamless integration in automated workflows
Marius, a biophysics expert at Johnson & Johnson Innovative Medicine, shares his insights into this rapidly evolving field of biomanufacturing.
Use this curated list of must-attend 2025 biologics conferences to plan your year. Find out when and where each conference takes place, who will be there, and what you can expect.
NanoTemper Technologies is entering a new chapter of leadership. After 16 years as Co-CEOs, Philipp Baaske and Stefan Duhr have redefined their roles to better position the company for continued growt
NanoTemper Technologies has established an advisory board consisting of five distinguished professionals, each a seasoned expert in their respective fields. This move underscores NanoTemper...
NanoTemper Technologies has established an advisory board consisting of five distinguished professionals, each a seasoned expert in their respective fields. This move underscores NanoTemper...
The work of pre-formulations scientists is critical to de-risk the entire development process for biologics. Read on to learn more about what to consider about your buffer components for...
Each excipient class helps stabilize biologics – from monoclonal antibodies to vaccine antigens – in different ways. Read on to learn more about some of the most important excipients for...
NanoTemper Technologies, well known for creating biophysical tools that accelerate the work of drug discovery researchers, brings their groundbreaking Spectral Shift technology to the protein...
Drug Discovery Chemistry is an annual event that focuses solely on early drug discovery, where scientists from around the world gather to showcase their research and participate in thoughtful...
Learn how it’s possible to use the Prometheus Panta to extrapolate how your low concentration sample will behave once it’s scaled up and at higher concentrations used for clinical administration.
Use this list of crowd-sourced favorites to kick-start your 2024 biologics conference plans. Find out when and where each conference takes place, who will be there, which topics are covered, and...
Attending dedicated targeted protein degradation conferences and tracks is a great way to keep up with this rapidly evolving field. Here are 8 conferences you’ll want to attend in 2024.
Antibody-drug conjugates, or ADCs, are revolutionary therapeutics that represent a growing proportion of the biologics market. They combine the targeting power of a monoclonal antibody, which is...
